Company news

InnoCare Pharma Ltd. news in 2025

InnoCare Pharma Ltd.'s news releases, calls and decks from 2025, newest first.

View company

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

December 23, 2025

InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

December 17, 2025

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

December 14, 2025

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

December 11, 2025

Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 9, 2025

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 8, 2025

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

November 27, 2025

Announcement on Adjusting the Nomination Committee Members of the Board of Directors

November 13, 2025

Announcement on Convening the Q3 2025 Performance Briefing

November 5, 2025

InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China

October 30, 2025

Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025

October 29, 2025

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

October 8, 2025

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore

September 7, 2025

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China

August 21, 2025

Announcement on Grant of Reserved Restricted Shares to Grantees

August 20, 2025

InnoCare Releases 2025 Interim Results and Business Highlights

August 19, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 11, 2025

Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant in 2023 STAR Market Restricted Stock Incentive Plan and Listing of Shares

July 15, 2025

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

July 3, 2025

Announcement on Resolution of the Board of Directors

June 20, 2025

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%

June 19, 2025

Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress

June 12, 2025

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting

June 1, 2025

Announcement on the Cash Management Using Some Temporarily Idle Raised Funds and Deposit of Raised Funds through Call Deposits and Agreement Deposits

May 29, 2025

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China

May 28, 2025

InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

May 21, 2025

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

May 16, 2025

Announcement on Signing Strategic Cooperation Framework Agreement and Scientific Research Cooperation Agreement with Westlake University and Related Party Transactions

May 13, 2025

InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA

May 11, 2025

Announcement on the Provision of Online Voting Reminder Service for the General Meeting

May 6, 2025

InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA

May 1, 2025

Notice on Convening the 2025 Annual General Meeting

April 28, 2025

InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

April 25, 2025

InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China

April 15, 2025

Announcement on Voluntary Disclosure of the Latest Research Results of Multiple Oncology Pipelines Selected for 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 8, 2025

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

March 27, 2025

InnoCare Releases 2024 Results and Business Highlights

March 27, 2025

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China

March 20, 2025

Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD

March 9, 2025

Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum

February 26, 2025

InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

February 17, 2025

Announcement on Appointment of Independent Non-executive Director

January 21, 2025

Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium

January 20, 2025

Annual Earnings Preannouncement for 2024

January 16, 2025

Decks in 2025